Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15:18 | NeuroSense Therapeutics announces $500,000 private placement | 1 | Seeking Alpha | ||
Di | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
20.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.08. | NeuroSense Therapeutics Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
01.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
10.07. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
26.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
12.05. | This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday | 19 | Benzinga.com | ||
NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
12.05. | Boral Capital starts NeuroSense stock with Buy, $14 target | 12 | Investing.com | ||
07.05. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
24.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
24.04. | NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update | 153 | PR Newswire | Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about... ► Artikel lesen | |
09.04. | NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment | 272 | PR Newswire | New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.
CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/... ► Artikel lesen | |
08.04. | NeuroSense Therapeutics GAAP EPS of -$0.54 | 3 | Seeking Alpha | ||
07.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
07.04. | NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates | 147 | PR Newswire | Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline
Ongoing partnership... ► Artikel lesen | |
07.04. | NeuroSense Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
27.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
25.03. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 25.03.2025 | 538 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.03.2025
Aktien
1 US50125G1094 KULR Technology Group... ► Artikel lesen | |
19.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CARDIOL THERAPEUTICS | 0,927 | -0,43 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
CIDARA THERAPEUTICS | 55,50 | +1,83 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics... ► Artikel lesen | |
QIAGEN | 40,215 | +0,11 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
EVOTEC | 5,702 | -2,70 % | Insiderkäufe und Datenpanne - Evotec, naoo AG, PayPal | In der deutschen Wirtschaft herrscht zunehmend Unruhe und nicht jeder Vorstand sitzt mehr sicher im Sattel. Der Volkswagen Konzern ist ins Straucheln geraten und die Frage, ob der Vorstandschef Oliver... ► Artikel lesen | |
BIONTECH | 89,05 | +3,37 % | BioNtech Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
MINERALYS THERAPEUTICS | 31,600 | +8,03 % | Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 | ||
SUMMIT THERAPEUTICS | 23,770 | +1,06 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
RECURSION PHARMACEUTICALS | 4,565 | -1,40 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
BOLT PROJECTS | 4,155 | +43,77 % | Bolt Projects Holdings, Inc. - 8-K, Current Report | ||
ADMA BIOLOGICS | 16,530 | -2,19 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,500 | -3,49 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
VALNEVA | 3,768 | -1,26 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
29.08.2025 / 16:48 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 11,575 | -2,73 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 19,490 | -1,42 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen | |
TAYSHA GENE THERAPIES | 3,235 | +11,55 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from... ► Artikel lesen |